"They found that about 68% of the patients with a PSA less than 1 actually had a positive test. And that's really important," says Jason M. Hafron, MD.
In an interview with Urology Times at the 2023 LUGPA Annual Meeting, Jason M. Hafron, MD, highlights data from a recent post-hoc analysis of the SPOTLIGHT trial exploring flotufolastat F 18 (Posluma) in patients with suspected biochemical recurrence who have low to very low PSA levels. Hafron is the chief medical officer and medical director of clinical research at the Michigan Institute of Urology, PC, and a professor of urology at the William Beaumont School of Medicine, Oakland University.
The SPOTLIGHT trial with Posluma, they did a post hoc analysis at ASTRO just recently. It's interesting; they looked at a segment of the study with the patients with very low PSAs. They found that about 68% of the patients with a PSA less than 1 actually had a positive test. And that's really important. It's important at multiple levels. It's important in the clinic, when you're counseling a patient to say that two-thirds of the time, we're going to find something on this test, and this test is worth it. It's also important when we're in the early stages of PET imaging, working with the payers, because sometimes we get push back at testing too early. I think based on the Posluma post hoc analysis, or the SPOTLIGHT post hoc analysis, it's pretty clear that we're finding disease. They even broke it down to less than .5. Even at .5 PSA, they were getting 64% positivity, and almost 30% extra prostatic spread, or out of the pelvis spread. So, there's significant disease that Posluma is finding in a very low PSA. In my practice, I just try to PET everyone early and as early as possible, because it can really make a difference in the management of these patients.
This transcription has been edited for clarity.